Medical
-
Dutch intranasal vaccine developer and CDMO Intravacc said that it has received an award of up to $14.6 million from the US National Institute of Allergy and Infectious Diseases (NIAID) to support development of an… Read more . . .
-
Synairgen has announced that the Phase 2 ACTIV-2 trial of SNG001 inhaled interferon-beta-1a in non-hospitalized COVID-19 patients failed to show a statistically significant reduction in hospitalization, viral load, safety, or resolution of symptoms compared to placebo,… Read more . . .
-
Odyssey Health announced that it has completed its Phase 1 study of PRV-002, a novel intranasal synthetic neurosteroid powder formulation that the company is developing for the treatment of concussion, and said that the results… Read more . . .
-
According to Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine has received a two-year $795,000 grant from the Alzheimer’s Association to support a Phase 2 trial of empagliflozin and intranasal insulin for… Read more . . .
-
On a form 8-k filed with the US Securities and Exchange Commission (SEC), United Therapeutics reported the following: “On September 20, 2022, United Therapeutics Corporation (the Company) announced the termination of the PERFECT clinical study… Read more . . .
-
Synairgen announced that it will present data from the Phase 3 SPRINTER trial of its SNG001 nebulized interferon-beta-1a in hospitalized COVID-19 patients at an upcoming meeting showing that treatment with SNG001 reduced symptoms of long… Read more . . .
-
Satsuma Pharmaceuticals announced that data from a portion of the Phase 3 ASCEND trial of the company’s STS101 dihydroergotamine (DHE) nasal powder where STS101 was delivered via a second generation device for the treatment of… Read more . . .
-
Startup Moat Biotechnology announced the initiation of a funding round led by Cortado Ventures that aims to raise up to $20 million for continued development of the company’s intranasal vaccine against COVID-19. According to the… Read more . . .
-
According to Tiziana Life Sciences, The ALS Association will award a Lawrence & Isabel Barnett Drug Development Program Grant to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital (BWH) for… Read more . . .
-
Bryn Pharma said that it has completed a pivotal study of its Utuly (BRYN-NDS1C) epinephrine nasal spray comparing PK/PD profiles of Utuly to a 0.3 mg dose of epinephrine delivered by autoinjector. According to the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK